ArticleNature communications2022
Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06738082 (Influenza Vaccine Elicited Immune Response in Immunocompromised Patients), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Association Between Immunosuppressive Cell Populations and Immune Response to Influenza Vaccination in Younger and Older Adults.Vaccines · 2026Article
- Associations between biological age acceleration and hospitalization burden of community-acquired pneumonia: a cohort study.GeroScience · 2026Article
- Human Organoids as a Novel Tool for Vaccine Study.Advanced healthcare materials · 2026Review
- Interferon-related inflammaging links epigenetic age acceleration to multimorbidity.Cell genomics · 2026Article
- Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential.Therapeutic innovation & regulatory science · 2026Review
- Multi-omics to study chronic respiratory diseases and viral infections.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Influenza vaccination post-COVID-19 expands vaccine-specific effector CD4 T-cells and Tregs under positive influence of host trained innate immunity.NPJ vaccines · 2025Article
- Limited Predictive Utility of Baseline Peripheral Blood Bulk Transcriptomics for Influenza Vaccine Responsiveness in Older Adults.Vaccines · 2025Article
- Pre-Vaccination Immunotypes and Immune Entropy Are Indicators of Multiple Vaccine Responsiveness.Aging cell · 2025Article
- Rapamycin for longevity: the pros, the cons, and future perspectives.Frontiers in aging · 2025Review
- Skewed pulmonary innate immune cell composition underlies the delayed influenza clearance in aged mice.Frontiers in microbiology · 2025Article
- Immune aging and infectious diseases.Chinese medical journal · 2024Review
- Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population.Science advances · 2024Article
- Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies.NPJ vaccines · 2024Review
- Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults.Nature immunology · 2024Article
- Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine.EBioMedicine · 2024Article
- Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults.medRxiv : the preprint server for health sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seasonal influenza outbreaks, especially in high-risk groups such as the elderly, represent an important public health problem. Prevailing inadequate efficacy of seasonal vaccines is a crucial bottleneck. Understanding the immunological and molecular mechanisms underpinning differential influenza vaccine responsiveness is essential to improve vaccination strategies. Here we show comprehensive characterization of the immune response of randomly selected elderly participants (≥ 65 years), immunized with the adjuvanted influenza vaccine Fluad. In-depth analyses by serology, multi-parametric flow cytometry, multiplex and transcriptome analysis, coupled to bioinformatics and mathematical modelling, reveal distinguishing immunological and molecular features between responders and non-responders defined by vaccine-induced seroconversion. Non-responders are specifically characterized by multiple suppressive immune mechanisms. The generated comprehensive high dimensional dataset enables the identification of putative mechanisms and nodes responsible for vaccine non-responsiveness independently of confounding age-related effects, with the potential to facilitate development of tailored vaccination strategies for the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.